人工肝支持系统对肝衰竭患者血清超敏C反应蛋白水平的影响

董丹丹; 严佑琴

doi:10.3969/j.issn.1001-5256.2014.10.011

人工肝支持系统对肝衰竭患者血清超敏C反应蛋白水平的影响

DOI: 10.3969/j.issn.1001-5256.2014.10.011

武汉市第七医院

详细信息

中图分类号: R318.14;R575.3
计量
- 文章访问数: 2229
- HTML全文浏览量: 15
- PDF下载量: 471
- 被引次数: 0
出版历程
- 收稿日期: 2014-07-21
- 出版日期: 2014-10-20

Clinical effect of artificial liver support system on serum hs-CRP level in patients with hepatic failure

The NO.7 Hospital of Wuhan

摘要

摘要:
目的通过观察人工肝支持系统对肝衰竭患者血清超敏C反应蛋白（hs-CRP）水平的影响,探讨hs-CRP水平改变对肝衰竭临床转归的影响。方法选取2011年11月-2013年12月在武汉市第七医院住院的患者134例,分为3组。分别测定经人工肝支持系统治疗的肝衰竭患者（n=60）及未行人工肝支持系统治疗的肝衰竭患者（n=37）治疗前后以及慢性乙型肝炎（CHB）患者（n=37）血清hs-CRP水平,并对结果进行统计分析。计量资料组间比较采用t检验,计数资料采用卡方检验。结果 3组患者治疗前均检测了hs-CRP的水平分别为（12.89±9.39）、（12.22±9.73）、（2.83±6.79）mg/L。人工肝治疗组与未行人工肝治疗组比较,差异无统计学意义（P值均>0.05）;肝衰竭两组与CHB组比较,差异均有统计学意义（P值均<0.001）。人工肝治疗组临床好转率为78.33%,与未行人工肝治疗组临床好转率54.05%相比,差异有统计学意义（χ2=6.315,P<0.05）;人工肝治疗有效组患者治疗后血清hs-CRP明显下降（t=5.344,P=0.000）,与人工肝治疗无效组...
- 肝功能衰竭 /
- 肝,人工 /
- C反应蛋白质
Abstract:
Objective To evaluate the clinical effect of artificial liver support system ( ALSS) on serum high-sensitivity C-reactive protein ( hs-CRP) level and investigate the influence of the change in hs-CRP level on clinical prognosis among patients with hepatic failure.Methods Patients were recruited into three groups: group one included 60 patients who received ALSS due to hepatic failure; group two included 37 patients with hepatic failure without ALSS treatment; and group three included 37 patients with chronic hepatitis B. The serum levels of hs-CRP were measured in groups two and three, and in group one before and after ALSS treatment. Comparison of continuous data between groups was made by t test, and comparison of categorical data was made by chi-square test. Results The levels of hs-CRP in group one before treatment and in groups two and three were 12. 89 ± 9. 39, 12. 22 ± 9. 73, and 2. 83 ± 6. 79, respectively. No significant difference in hs-CRP level between group one and group two was observed ( P > 0. 05) . However, the hs-CRP level in group three was significantly different from those in group one and group two ( P < 0. 001) . The improvement rate in group one after ALSS treatment ( 78.3%) was significantly higher compared with that in group two ( 54.05%) ( χ2= 6. 315, P < 0. 05) . ALSS treatment ( t = 5. 179, P <0. 05) . ALSS treatment was selectively effective in a subgroup of patients and greatly decreased the hs-CRP level in these patients ( t =5. 344, P = 0. 000) , resulting in a significant difference from the patients who were unresponsive to ALSS treatment ( t = 2. 368, P =0. 038) . Conclusion Artificial liver support system can decrease the hs-CRP level in patients with hepatic failure. Serum level of hs-CRP can be used as a clinical indicator of disease progression and predict the clinical outcomes of ALSS in patients with hepatic failure.
- liver failure /
- liver, artifical /
- C-reactive protein

HTML全文

参考文献(13)

[1]LI LJ.Difficulties and focuses in the treatment of liver failure[J].Chin J Hepatol, 2012, 20 (6) :405-407. (in Chinese) 李兰娟.肝衰竭临床治疗中的难点和热点[J].中华肝脏病杂志, 2012, 20 (6) :405-407.

[2] Liver Failure and Artificial liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association;Severe Liver Diseases and Artificial liver Group, Chinese Society of Hepatology, Chinese Medical Association.Diagnostic and treatment guidelines for liver failure[J].Chin J Clin Infect Dis, 2012, 5 (6) :321-327. (in Chinese) 中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会, 肝病学分会重型肝病与人工肝学组.肝衰竭诊治指南 (2012年版) [J].中华临床感染病杂志, 2012, 5 (6) :321-327.

[3]LIANG ZH.Value of high-sensitivity C-reactive protein in diagnosis of liver diseases[J].China Modern Med, 2010, 17 (18) :74-75. (in Chinese) 梁展华.超敏C-反应蛋白在肝病诊断中的应用价值[J].中国当代医药, 2010, 17 (18) :74-75.

[4]SASAKI K, FUJITA I, HAMASAKI Y, et al.Differentiating between bacterial and viral infection by measuring both C-reactive protein and2’-5’-oligoa-denylate synthetase inflammatory markers[J].J Infect Chemother, 2002, 8 (1) :76-80.

[5] YE YN, GAO ZL.Three shock hypotheses that may induce liver failure[J].Chin J Hepatol, 2009, 17 (8) :638-640. (in Chinese) 叶一农, 高志良.乙型肝炎肝衰竭发生机制中的三重打击[J].中华肝脏病杂志, 2009, 17 (8) :638-640.

[6]HAN DW.Enterogenous endotoxin hematic disease and liver disease[M].Beijing:China Science and Technology Press, 2004. (in Chinese) 韩德五.肠源性内毒素血症与肝病[M].北京:中国科学技术出版社, 2004.

[7]ROCEN M, KIESLIEHOVA E, MERTA D, et al.The effect of Prometheus device on laboratory markers of inflammation and tissue regeneration in acute liver failure management[J].Transplant Proc, 2010, 42 (9) :3606-3611.

[8]WANG MX.Changes in C-reactive protein among 124 patients with chronic severe hepatitis[J].Lab Med Clin, 2011, 8 (1) :2234-2235. (in Chinese) 汪明星.C反应蛋白在124例慢性重型肝炎中的变化[J].检验医学与临床, 2011, 8 (1) :2234-2235.

[9]MAO WL, CHEN Y, CHEN YM, et al.Change of serum cytokine levels in patients with acute on chronic liver failure treated by plasma exchange[J].J Clin Gastroenterol, 2011, 45 (6) :551-555.

[10]LI TY, WANG WJ, ZHANG SP, et al.Expressions of IL-18、IL-12 and IFN-γin chronic severe hepatitis and treatment with artificial liver support system[J].Jiangsu Med J, 2008, 34 (5) :438-440. (in Chinese) 李天一, 叶卫江, 张松平, 等.慢性重型肝炎患者血清IL-18、IL-12和IFN-γ的表达及人工肝治疗[J].江苏医药, 2008, 34 (5) :438-440.

[11]WANG YC, ZHANG M, LI YQ, et al.Clinical efficacy of artifical liver (plasma exchange) in treatment of liver failure among patients with chronic severe hepatitis[J].Chin Hepatol, 2012, 17 (8) :570-571. (in Chinese) 王英超, 张敏, 李永勤, 等.人工肝 (血浆置换) 治疗慢性重型肝炎肝功能衰竭的临床初探[J].肝脏, 2012, 17 (8) :570-571.

[12]WANG XH, YE YN, LIANG MF, et al.Plasma exchange combined with hemofiltration influences serum levels of IL-17 and IL-6 in patients with HBV-related acute-on-chronic liver failure[J].J Clin Hepatol, 2012, 28 (10) :756-763. (in Chinese) 王向槐, 叶一农, 梁敏锋, 等.血浆置换联合血液滤过对乙型肝炎相关慢加急性肝衰竭患者血清IL-17和IL-6的影响[J].临床肝胆病杂志, 2012, 28 (10) :756-763.

[13]ZHOU J, WAN H.Relationship between changes in serum cytokine levels after artificial liver therapy and clinical prognosis in patients with liver failure[J].J Clin Hepatol, 2013, 29 (7) :535-537. (in Chinese) 周渐, 万红.肝衰竭患者血浆置换治疗前后细胞因子的变化与预后的关系[J].临床肝胆病杂志, 2013, 29 (7) :535-537.

施引文献

资源附件(0)

访问统计